← 홈

림프종

650개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 650개
CGTBiologicstaleRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 0%임상시험 31상태 ACTIVE
AntibodystaleBiogenPhase 2

90-Y-ibritumomab tiuxetan (90-Y-ibritumomab tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+2
효능 ORR 89%임상시험 30상태 ACTIVE
AntibodyRochevedotin and anti-CD19 chime…Phase 2

Acalabrutinib combination with Rituximab (Acalabrutinib combination with Rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 66.4%임상시험 30상태 RECRUITING
ADCBiologicstaleSeagen Inc.Phase 2

Adriamycin, vinblastine, and dacarbazine (Adriamycin, vinblastine, and dacarbazine)

Hodgkin Lymphoma · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 96%임상시험 30상태 ACTIVE
CGTBiologicChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING
CGTBiologicInstituto de Investigación Hosp…Phase 1

Autologous CD19/CD22 CAR T cells (Autologous CD19/CD22 CAR T cells)

Precursor Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 30상태 RECRUITING
AntibodystaleRochePhase 2

Bendamustine + Rituximab (Bendamustine + Rituximab)

Marginal Zone Lymphoma(MZL) · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 RECRUITING
CGTBiologicstaleMinsk Scientific-Practical Cent…Phase 2

CD19+22 CAR-T cells (CD19+22 CAR-T cells)

Acute Lymphobkastic Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 1%임상시험 30상태 RECRUITING
ADCBiologicstaleEisai Inc.Phase 2

DOC Group B (DOC Group B)

Non-hodgkin Lymphoma; Hodgkin Lymphoma · Non-hodgkin Lymphoma

#Non-hodgkinLymphoma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 30상태 RECRUITING
ADCBiologicstaleVerastem, Inc.Phase 2

Defactinib (Defactinib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 3.2%임상시험 30상태 RECRUITING
AntibodystaleAlliance for Clinical Trials in…Phase 2

Epratuzumab (Epratuzumab)

Lymphoma · Leukemia

#Leukemia#Antibody#Phase2#항체#면역항체+3
효능 ORR 95%임상시험 30상태 DISCONTINUED
AntibodystaleGrupo Español de Linfomas y Tra…Phase 2

Zevalin (Ibritumomab Tiuxetan, Ibritumomab Tiuxetan (Zevalin))

Non-Hodgkin Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#항체#면역항체+3
효능 ORR 16%임상시험 30상태 ACTIVE
AntibodystaleADC TherapeuticsPhase 3

Loncastuximab tesirine (Loncastuximab tesirine)

Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#Antibody#Phase3#항체#면역항체+4
효능 ORR 94.1%임상시험 30상태 RECRUITING
ADCBiologicstaleChinese Academy of Medical Scie…Preclinical

Maintenance therapy-chidamide (Maintenance therapy-chidamide)

CD30+ Peripheral T-cell Lymphoma · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 30상태 RECRUITING
AntibodystaleJohn ReneauPhase 1

Mogamulizumab (Mogamulizumab)

Recurrent Adult T-Cell Leukemia/Lymphoma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma · Cutaneous T Cell Lymphoma

#CutaneousTCellLymphoma#Antibody#Phase1#항체#면역항체+5
효능 ORR 25%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 1)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 7%임상시험 30상태 RECRUITING
AntibodystaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab cohort 2)

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 37.8%임상시험 30상태 RECRUITING
ADCBiologicstaleFondazione Italiana Linfomi - E…Phase 2

R-DHAP (R-DHAP)

Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B-cell Lymphoma Recurrent · DLBCL

#DLBCL#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 51.4%임상시험 30상태 DISCONTINUED
ADCBiologicstaleCalithera Biosciences, IncPhase 2

Sapanisertib (Sapanisertib)

Advanced Lymphoma; Advanced Malignant Solid Neoplasm · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 18.4%임상시험 30상태 RECRUITING
AntibodystaleTG Therapeutics, Inc.Phase 2

Ublituximab (Ublituximab)

Non-Hodgkins Lymphoma; B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase2#항체#면역항체+4
효능 ORR 84.4%임상시험 30상태 ACTIVE

7 / 33 페이지

← 이전다음 →